The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...

Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...

Hims & Hers (NYSE: HIMS) has skyrocketed 120% in just a month! Is it the next big disruptor in healthcare, or is it ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...

Analysts have recently evaluated Hims & Hers Health and provided 12-month price targets. The average target is $36.43, ...

Shares of Hims & Hers (NYSE: HIMS) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the ...

Fintel reports that on February 18, 2025, Morgan Stanley downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from ...

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

Shares of Hims & Hers Health (HIMS) are down at the time of writing after Morgan Stanley, led by four-star analyst Craig Hettenbach, ...

BTIG analyst David Larsen raised the firm’s price target on Hims & Hers (HIMS) to $85 from $35 and keeps a Buy rating on the shares. The ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...